Why the study?
Does prophylactic substrate-based catheter ablation reduce the incidence of ICD therapy in patients with a history of myocardial infarction who received ICDs for the secondary prevention of sudden death?
Does prophylactic substrate-based catheter ablation reduce the incidence of ICD therapy in patients with a history of myocardial infarction who received ICDs for the secondary prevention of sudden death?
Prophylactic substrate-based catheter ablation reduces the incidence of ICD therapy in patients with prior MI receiving ICDs for secondary prevention.
Supports prophylactic ablation to reduce ICD therapies in post-MI secondary prevention; extends substrate-based evidence to randomized setting.
In this randomized trial, prophylactic substrate-based catheter ablation reduced the incidence of ICD therapy in patients with a history of myocardial infarction who received ICDs for the secondary prevention of sudden death. (Current Controlled Trials number, ISRCTN62488166 [controlled-trials.com].).
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: